This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quenelle, D. C.
Right arrow Articles by Kern, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quenelle, D. C.
Right arrow Articles by Kern, E. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2007, p. 4118-4124, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00762-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Synergistic Efficacy of the Combination of ST-246 with CMX001 against Orthopoxviruses{triangledown}

Debra C. Quenelle,1* Mark N. Prichard,1 Kathy A. Keith,1 Dennis E. Hruby,2 Robert Jordan,2 George R. Painter,3 Alice Robertson,3 and Earl R. Kern1

University of Alabama School of Medicine, Birmingham, Alabama,1 SIGA Technologies, Inc., Corvallis, Oregon,2 Chimerix Inc., Durham, North Carolina3

Received 13 June 2007/ Returned for modification 5 July 2007/ Accepted 10 August 2007

The combination of ST-246 and hexadecyloxypropyl-cidofovir or CMX001 was evaluated for synergistic activity in vitro against vaccinia virus and cowpox virus (CV) and in vivo against CV. In cell culture the combination was highly synergistic against both viruses, and the results suggested that combined treatment with these agents might offer superior efficacy in vivo. For animal models, ST-246 was administered orally with or without CMX001 to mice lethally infected with CV. Treatments began 1, 3, or 6 days postinfection using lower dosages than previously used for single-drug treatment. ST-246 was given at 10, 3, or 1 mg/kg of body weight with or without CMX001 at 3, 1, or 0.3 mg/kg to evaluate potential synergistic interactions. Treatment beginning 6 days post-viral inoculation with ST-246 alone only increased the mean day to death at 10 or 3 mg/kg but had no effect on survival. CMX001 alone also had no effect on survival. When the combination of the two drugs was begun 6 days after viral infection using various dosages of the two, a synergistic reduction in mortality was observed. No evidence of increased toxicity was noted with the combination either in vitro or in vivo. These results indicate that combinations of ST-246 and CMX001 are synergistic both in vitro and in vivo and suggest that combination therapy using ST-246 and CMX001 for treatment of orthopoxvirus disease in humans or animals may provide an additional benefit over the use of the two drugs by themselves.

* Corresponding author. Mailing address: The University of Alabama at Birmingham, Department of Pediatrics, 128 Children's Harbor Building, 1600 6th Avenue South, Birmingham, AL 35233-1711. Phone: (205) 934-1990. Fax: (205) 975-1992. E-mail: dquenell{at}uab.edu

{triangledown} Published ahead of print on 27 August 2007.

Antimicrobial Agents and Chemotherapy, November 2007, p. 4118-4124, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00762-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Huggins, J., Goff, A., Hensley, L., Mucker, E., Shamblin, J., Wlazlowski, C., Johnson, W., Chapman, J., Larsen, T., Twenhafel, N., Karem, K., Damon, I. K., Byrd, C. M., Bolken, T. C., Jordan, R., Hruby, D. (2009). Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246. Antimicrob. Agents Chemother. 53: 2620-2625 [Abstract] [Full Text]  
  • Jordan, R., Goff, A., Frimm, A., Corrado, M. L., Hensley, L. E., Byrd, C. M., Mucker, E., Shamblin, J., Bolken, T. C., Wlazlowski, C., Johnson, W., Chapman, J., Twenhafel, N., Tyavanagimatt, S., Amantana, A., Chinsangaram, J., Hruby, D. E., Huggins, J. (2009). ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification. Antimicrob. Agents Chemother. 53: 1817-1822 [Abstract] [Full Text]  
  • Kern, E. R., Prichard, M. N., Quenelle, D. C., Keith, K. A., Tiwari, K. N., Maddry, J. A., Secrist, J. A. III (2009). Activities of Certain 5-Substituted 4'-Thiopyrimidine Nucleosides against Orthopoxvirus Infections. Antimicrob. Agents Chemother. 53: 572-579 [Abstract] [Full Text]  
  • McSharry, J. J., Deziel, M. R., Zager, K., Weng, Q., Drusano, G. L. (2009). Pharmacodynamics of Cidofovir for Vaccinia Virus Infection in an In Vitro Hollow-Fiber Infection Model System. Antimicrob. Agents Chemother. 53: 129-135 [Abstract] [Full Text]  
  • Prichard, M. N., Hartline, C. B., Harden, E. A., Daily, S. L., Beadle, J. R., Valiaeva, N., Kern, E. R., Hostetler, K. Y. (2008). Inhibition of Herpesvirus Replication by Hexadecyloxypropyl Esters of Purine- and Pyrimidine-Based Phosphonomethoxyethyl Nucleoside Phosphonates. Antimicrob. Agents Chemother. 52: 4326-4330 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»